Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapy of genital herpes with topically applied interferon.

Literature DB >> 3310870

Therapy of genital herpes with topically applied interferon.

L J Eron¹, C Toy, B Salsitz, R R Scheer, D L Wood, P I Nadler.

Abstract

Ninety-four patients with recurrences of genital herpes were randomized in a double-blind trial to receive topical therapy for 5 days with either alpha-2a interferon at 30 X 10(6) IU/ml or 10 X 10(6) IU/ml or placebo six times daily. No differences were noted between either interferon dose and placebo with respect to the duration of viral shedding, the time to crusting, or the time to healing of herpetic lesions. Aqueous solutions of alpha-2a interferon applied topically to unroofed vesicles do not appear to be clinically useful in the treatment of recurrences of genital herpes.

Entities: Species

Mesh：

Substances：

Year: 1987 PMID： 3310870 PMCID： PMC174885 DOI： 10.1128/AAC.31.7.1137

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

15 in total

1. Efficacy of topical acyclovir cream in first and recurrent episodes of genital herpes.

Authors: G R Kinghorn; E B Turner; I G Barton; C W Potter; C A Burke; A P Fiddian
Journal: Antiviral Res Date: 1983-12 Impact factor: 5.970

2. Combination therapy of dendritic keratitis with trifluorothymidine and interferon.

Authors: R Sundmacher; K Cantell; D Neumann-Haefelin
Journal: Lancet Date: 1978-09-23 Impact factor: 79.321

3. Combination therapy for dendritic keratitis with human leucocyte interferon and trifluorothymidine.

Authors: E W de Koning; O P van Bijsterveld; K Cantell
Journal: Br J Ophthalmol Date: 1982-08 Impact factor: 4.638

4. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial.

Authors: R C Reichman; G J Badger; G J Mertz; L Corey; D D Richman; J D Connor; D Redfield; M C Savoia; M N Oxman; Y Bryson
Journal: JAMA Date: 1984-04-27 Impact factor: 56.272

5. Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infection.

Authors: S L Spruance; M B McKeough; J R Cardinal
Journal: Antimicrob Agents Chemother Date: 1984-01 Impact factor: 5.191

6. Interferon in the prevention of genital herpes recurrence.

Authors: L J Eron; L Harvey; C Toy; D Santomauro
Journal: Antimicrob Agents Chemother Date: 1986-10 Impact factor: 5.191

7. Combination therapy for dendritic keratitis with acyclovir and alpha-interferon.

Authors: E W de Koning; O P van Bijsterveld; K Cantell
Journal: Arch Ophthalmol Date: 1983-12

8. Pathogenesis of herpes simplex labialis: correlation of vesicle fluid interferon with lesion age and virus titer.

Authors: S L Spruance; J A Green; G Chiu; T J Yeh; G Wenerstrom; J C Overall
Journal: Infect Immun Date: 1982-06 Impact factor: 3.441

9. The role of interferon in the resistance of C57BL/6 mice to various doses of herpes simplex virus type 1.

Authors: R Zawatzky; I Gresser; E DeMaeyer; H Kirchner
Journal: J Infect Dis Date: 1982-09 Impact factor: 5.226

Review 10. Genital herpes simplex virus infections: clinical manifestations, course, and complications.

Authors: L Corey; H G Adams; Z A Brown; K K Holmes
Journal: Ann Intern Med Date: 1983-06 Impact factor: 25.391

6 in total

1. Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model.

Authors: N Weiner; N Williams; G Birch; C Ramachandran; C Shipman; G Flynn
Journal: Antimicrob Agents Chemother Date: 1989-08 Impact factor: 5.191

Review 2. Current recommendations for the treatment of genital herpes.

Authors: D T Leung; S L Sacks
Journal: Drugs Date: 2000-12 Impact factor: 9.546

3. Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections.

Authors: D I Bernstein; C J Harrison
Journal: Antimicrob Agents Chemother Date: 1989-09 Impact factor: 5.191

4. Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies.

Authors: K Egbaria; C Ramachandran; D Kittayanond; N Weiner
Journal: Antimicrob Agents Chemother Date: 1990-01 Impact factor: 5.191

5. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.

Authors: F Chen; K H Chan; Y Jiang; R Y T Kao; H T Lu; K W Fan; V C C Cheng; W H W Tsui; I F N Hung; T S W Lee; Y Guan; J S M Peiris; K Y Yuen
Journal: J Clin Virol Date: 2004-09 Impact factor: 3.168

Review 6. Medical treatment of viral pneumonia including SARS in immunocompetent adult.

Authors: V C C Cheng; B S F Tang; A K L Wu; C M Chu; K Y Yuen
Journal: J Infect Date: 2004-11 Impact factor: 6.072

6 in total